The overall goals ofthe Development Fund Program are to 1) provide seed funding for novel, creative and early, high risk research projects, 2) promote interdisciplinary research projects and 3) recruit new investigators into the field of cancer molecular imaging. This funding mechanism has had a significant impact on the discovery of important aspects of tumor biology through a) the use of in vivo imaging, b) the development of novel technologies and agents, and c) the advancement of research tools from bench to bedside and back. In the past, this type of funding mechanism has led to significant discoveries within our Center, including the creation of enzyme-activatable imaging probes and magnetic cell trackers or fusion proteins to image gene expression. Two specific Developmental Fund projects were identified for the first year of funding. The first project ("New candidate molecular imaging targets for pancreatic ductal adenocarcinoma from functional genomics") identified cathepsin E (CTSE) as a novel PDAC-specific imaging target based on large scale genomic profiling.
The specific aims are to 1) synthesize and characterize a cell permeable affinity based probe for CTSE and then perform proof-of-principle studies (histochemistry, cell based imaging) and 2) to validate the imaging probe in the Kras/p53 genetically engineered mouse model of PDAC. The second project ("Intraoperative single cell imaging of sarcoma resection") applies recent advances in intraoperative imaging systems and probes to the resection of soft tissue sarcoma. The PI hypothesize that the use of multiple markers, visualized at cellular resolution, will provide more complete information during surgery, not only by conveying the location of neoplastic cells, but also by informing on the infiltration or encapsulation status ofthe border regions.
The specific aims are to 1) synthesize and test imaging probes (EGFR-targeted, host probes and neovasculature) in a mouse model of sarcoma and 2) develop a mathematical framework for describing theoretical pharmacokinetics to address constraints such as probe type, administration route, and imaging performance as a function of biomarker expression. Additional applications will be solicited in subsequent years and peer reviewed by the Internal Steering Committee. Priority will be given to proposals which 1) are interdisciplinary and involve a synthesis of molecular/cellular and imaging sciences, 2) make synergistic use ofthe Specialized Resources and 3) employ highly innovative concepts
|Keliher, Edmund J; Klubnick, Jenna A; Reiner, Thomas et al. (2014) Efficient acid-catalyzed (18) F/(19) F fluoride exchange of BODIPY dyes. ChemMedChem 9:1368-73|
|Dubach, J Matthew; Vinegoni, Claudio; Weissleder, Ralph (2014) Steady state anisotropy two-photon microscopy resolves multiple, spectrally similar fluorophores, enabling in vivo multilabel imaging. Opt Lett 39:4482-5|
|Pittet, Mikael J; Nahrendorf, Matthias; Swirski, Filip K (2014) The journey from stem cell to macrophage. Ann N Y Acad Sci 1319:1-18|
|Thurber, Greg M; Reiner, Thomas; Yang, Katherine S et al. (2014) Effect of small-molecule modification on single-cell pharmacokinetics of PARP inhibitors. Mol Cancer Ther 13:986-95|
|Courtis, Alexandra M; Santos, Sofia A; Guan, Yinghua et al. (2014) Monoalkoxy BODIPYs--a fluorophore class for bioimaging. Bioconjug Chem 25:1043-51|
|Hideshima, T; Mazitschek, R; Santo, L et al. (2014) Induction of differential apoptotic pathways in multiple myeloma cells by class-selective histone deacetylase inhibitors. Leukemia 28:457-60|
|Kim, Eunha; Yang, Katherine S; Giedt, Randy J et al. (2014) Red Si-rhodamine drug conjugates enable imaging in GFP cells. Chem Commun (Camb) 50:4504-7|
|Dubach, J M; Vinegoni, C; Mazitschek, R et al. (2014) In vivo imaging of specific drug-target binding at subcellular resolution. Nat Commun 5:3946|
|Turetsky, Anna; Kim, Eunha; Kohler, Rainer H et al. (2014) Single cell imaging of Bruton's tyrosine kinase using an irreversible inhibitor. Sci Rep 4:4782|
|Aceto, Nicola; Bardia, Aditya; Miyamoto, David T et al. (2014) Circulating tumor cell clusters are oligoclonal precursors of breast cancer metastasis. Cell 158:1110-22|
Showing the most recent 10 out of 266 publications